University of #Penn refuses to stop innovating. After having introduced CAR-T to the fight against #cancer, another Penn team has developed an a related technology which has produced positive results in animal trials. Chimeric Antigen Receptor T cells, or CAR-T, has demonstrated success in treating #bloodcancer, but falls short against solid tumors. The Penn team's new technology, Chimeric Antigen Receptor Macrophages or CAR-M, leverages a similar process of altering the pati

Imalumab is the only drug targeting oxMIF to reach #clinicaltrials, but ultimately was terminated due to poor overall benefit-risk assessment. Now, OncoOne has announced that they have invested in three different modalities targeting oxMIF via distinct mechanisms of action, see link below. Through #aitechnology, Kognitic’s platform will automatically capture the emergence of assets directed at this under-the-radar target and details of their clinical trials, such as other dru

Merck KGaA's MET inhibitor, Tepotinib, received approval in Japan for #NSCLC yesterday, gaining a lead in the tight race against Capmatinib - Novartis' MET inhibitor. The two continue to strive for approval in the United States. #Kognitic's platform highlights the timeline for ongoing trials for both these drugs below. The approval for Tepotinib comes from Merck KGaA's ongoing Vision trial. #Oncology #Analytics #AI #Cancer #LungCancer #Data #Automated #Pharma #MachineLearning

The National Institute for Health and Care Excellence has recommended #Lynparza for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or primary peritonealcancer in adults with a BRCA1 or BRCA2 mutation (see link below). NICE reported this endorsement is due to recent evidence from #clinicaltrials. Using #Kognitic's breadth of filters, our clients can access all Lynparza trials in this #patientsegment instantly! #OvarianCancer #Olaparib #Cancer #Au